Emrick Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.30 M
About Emrick Pharmaceuticals
Emrick Pharmaceuticals Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 September 2012 and has a history of 12 years and five months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.30 M.
Mohd Javed and Saba Khan serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232DL2012PTC241840
-
Company No.
241840
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Sep 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Emrick Pharmaceuticals Private Limited offer?
Emrick Pharmaceuticals Private Limited offers a wide range of products and services, including Liver Supplement, Ayurvedic Liver Tonic, Pharmaceutical Medicine, Lycopene Syrup, Digestive System Drugs & Medicines, Pantoprazole Drugs, Pain Relief Drugs & Pharmaceuticals, Pain Reliever Gel, API (Active Pharmaceutical Ingredients), Montelukast Sodium Powder.
Who are the key members and board of directors at Emrick Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohd Javed
|
Director | 07-Sep-2012 | Current |
|
Saba Khan
|
Director | 07-Sep-2012 | Current |
Financial Performance of Emrick Pharmaceuticals.
Emrick Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Emrick Pharmaceuticals?
In 2017, Emrick Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.30 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.13 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Jun 2021 | Canara Bank | ₹1.30 M | Open |
How Many Employees Work at Emrick Pharmaceuticals?
Unlock and access historical data on people associated with Emrick Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emrick Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emrick Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
